In previous studies, ILA has been reported to interfere with IL-2-driven generation of lymphokine-activated killer (LAK) activity. In this investigation, we have demonstrated that IL4 inhibited the IL-2-induced differentiation of large granular lymphocytes (LGL) into LAK effectors by a mechanism involving, at least in part, an increase in LGL intracellular cAMP levels. In contrast, with its capacity to induce cAMP accumulation in resting LGL, IL4 had a very negligible effect on LAK activity induction, and cAMP levels increase in LGL that had been preincubated with IL-2. Furthermore, the inhibitory effect of IL4 on LAK activity generation also correlated with a marked decrease in N-CBZ-L-lysine thiobenzylester esterase activity, with an inhibition of tumor necrosis factor (TNF) mRNA expression and TNF production by IL-2-stimulated LGL. These results strongly suggest that complex signaling processes could be ascribed to the dual activities of cytokines and their interplay in LAK promotion. (J. Clin. Invest. 1990Invest. . 85:1909Invest. -1913.) cyclic adenosine monophosphatev cytokine interplay * lymphokine-activated killer Introduction Cytokines form a network of regulatory signals and several
Introduction
Cytokines form a network of regulatory signals and several lines of evidence suggest the existence of a considerable overlap in their activities which leads to unexpected patterns of synergism or antagonism. First reported as a B cell stimulatory factor, interleukin 4 (IL-4) has been found to exhibit a wide range of cell activation properties on various types of immunocompetent cells in a species specific manner (1) (2) (3) (4) . IL-4 is reported to exert both positive and negative regulatory effects on the generation of non-MHC-restricted cytotoxicity (5) (6) (7) (8) (9) (10) . It has been demonstrated that addition ofrecombinant human IL-4 strongly inhibits the interleukin 2 (IL-2)-mediated proliferation and differentiation of human resting peripheral blood lymphocytes (PBL) into lymphokine-activated killer (LAK)' effectors (5, 9, 10). However, recent reports suggest that the immunoregulatory properties of IL-4 on non-MHC-restricted cytotoxicity are dependent on the cell activation state (5, 9) . While having no effect alone on non-MHC-restricted lytic capacity of resting human PBL (5, 7-10), IL-4 by itself is able to selectively enhance LAK activity of IL-2-prestimulated PBL and large granular lymphocytes (LGL) (9, 10) . The precise molecular mechanism underlying the antagonistic effect of IL-2 and IL- 4 has not yet been established. Moreover, the signal transduction pathway of human is not yet known. The inhibitory properties of cyclic AMP (cAMP) and cAMPinducing agents for several immune responses (1 1-14) such as IL-2-induced cell activation have been well documented (15, 16) . Although there are several important questions regarding the role ofN-CBZ-L-lysine thiobenzylester esterase (BLT-E) in cell-mediated cytotoxicity (17, 18) , there is a prevailing view that an elevated BLT-E activity seems to correlate with cytotoxic activity (19, 20) . We questioned whether or not the IL-4 inhibitory effect on IL-2-driven LGL differentiation and the subsequent acquisition of their lytic potential involves the cAMP pathway. In this report, we demonstrate that heightened cAMP levels resulting from IL-2/IL-4 costimulation of LGL interfere with the transmission of the IL-2 signal leading to LAK promotion by inhibiting the serine esterase increase and TNF mRNA expression in LGL.
Methods
Cell preparation. Fresh human large granular lymphocytes were purified as previously described (21 LGL were incubated 10 or 30 min in complete medium in presence ofthe indicated lymphokines or forskolin, then centrifuged 5 min at 2,000 rpm, resuspended in a lysis buffer (sodium acetate 50 mM) and placed 5 min in liquid nitrogen and 2 min in a boiling water bath. cAMP was measured in cell lysates using a cAMP kit assay (TRK432, Amersham, les Ulis, France) according to the kit procedure. Briefly, samples and standards were incubated 3 h at 4°C in presence of tritiated cAMP before addition of charcoal, which binds cAMP with a high affinity. Charcoal and supernatant were separated by centrifugation 5 min at 2000 g. Supernatants containing nonadsorbed cAMP were collected and tritiated cAMP was measured in triplicates in a scintillation counter (LKB Produkter).
BLT-E assay. After 3 d ofincubation in complete medium with or without IL-2 and/or IL-4, LGL were lysed by incubating 107 cells/ml in PBS containing 0.5% Nonidet P40 (Sigma Chemical Co.) at 4°C for 30 min. Serine esterase activity in 50 ul of cell lysates was determined by measuring the clivage of N-CBZ-L-Lys-thiobenzyl ester (BLT, Sigma Chemical Co.) as reported (17) . Each assay was performed in triplicate. The absorbance at 420 nm was measured after 2 h at room temperature using a microplate ELISA reader (Titertek Multiscan, MC, Helsinki, Finland). In all cases, the OD ofa blank well containing sample but lacking BLT was substracted from that with substrate. An absorbance of 1.0 U of O.D. after 2 h was defined as 1 U of BLT-E activity.
Evaluation of TNF-a mRNA expression. LGL (106 cells/ml) were incubated for 6 h in complete medium in the presence ofthe indicated lymphokines. Cytoplasmic RNA were obtained according to the procedure described (23) . Dilutions of denatured RNA of 2 X 106 cells were applied with suction to nylon sheet using a 96-well Minifold apparatus. After an 18-h hybridization at 65°C with either an [a-32P]-dCTP (Amersham)-labeled TNF DNA probe or a ft-actin DNA probe, nylon sheets were washed 30 min in 2X SSC and 0.2X SSC at 65°C and then exposed to x-ray films at -70°C for 3 d as described (24) . TNF-a and #l-actin DNA probes were labeled using the Multiprime DNA labeling systems (RPN1601Y, Amersham) according to the kit procedure.
Measurement ofimmunoreactive TNF-a. LGL (106 cells/ml) were incubated for 24 h in complete medium in presence of the indicated lymphokines. Supernatants were then collected and stored frozen at -20°C until the assay. Quantification of immunoreactive TNF-a was performed using an immunoradiometric method (TNF a-IRMA, Medgenix Diagnostics, Fleurus, Belgium) according to the kit procedure. The TNF-a IRMA does not cross-react with TNF-fl. Table I indicate that costimulation of LGL with IL-2 (2 ng/ml) and an inhibitory concentration of IL-4 (100 U/ml) for LAK generation resulted in a marked increase of intracellular cAMP (fourfold) compared with the basal level. Incubation of LGL with the same concentrations of IL-4 alone leads to a less important increase of cAMP levels (2.5-fold) compared with what is observed with the combination of both cytokines whereas IL-2 alone did not significantly affect cAMP level. Our results indicate that cAMP increased to a maximal level IL-4 inhibits BLT-E activity in LAK effectors. To gain more insight into the inhibitory effect of IL-4 on IL-2-driven LAK generation, we asked whether this lymphokine could affect the serine esterase activity in LGL, such as the BLT-E, suggested to be a marker of NK and CTL lytic capacity (17, 18) . We investigated then the effect of IL-4 on the intracellular BLT-E activity in IL-2-activated LGL. Results presented in Fig. 1 indicate that the acquisition of the lytic competence of LAK effectors towards Daudi target was accompanied by a 2.5-fold increase in the intracellular BLT-E activity. Addition of inhibitory concentrations of IL-4 at the initiation of the culture markedly reduced the intracellular content of BLT-E in a dose-dependent manner. This decrease directly correlated with the level of cytotoxicity measured against Daudi target. Addition of dBcAMP (10-4 M) at the initiation of the culture similarly resulted in a significant decrease of BLT-E activity, concomitantly with an inhibition of LAK cytotoxic function of IL-2-activated LGL. IL-4 inhibits TNF mRNA expression and TNF production by IL-2 activated LGL. IL-2 has been shown to induce TNF mRNA expression in LGL and TNF biological activity release in the culture medium, a phenomenon partially associated with acquisition of LAK activity by LGL (12, 25) . To examine whether the inhibitory effect of ILA4 on IL-2-induced LAK generation interferes with TNF release, we have first investigated the effect of IL-4 on TNF mRNA expression in IL-2-activated LGL. Dot blot hybridization using a cDNA TNF probe (Fig. 2) shows that addition of a concentration of IL-4 (100 U/ml) able to inhibit LAK generation strongly reduces TNF mRNA expression in IL-2-stimulated LGL. It is also shown in this figure that addition ofdBcAMP (10-4 M) also resulted in a marked inhibition of TNF mRNA expression in IL-2-stimu-lated LGL. Rehybridization ofthe same filter with a beta actin cDNA probe confirmed that all samples contained similar amounts of RNA (not shown). To further investigate the effect of IL-4 on TNF release by IL-2-activated LGL, we measured TNF in LGL supernatants after 24 h ofincubation in the same conditions (Fig. 2) . Data presented here show that IL-2 induces the production of detectable concentrations of TNF by LGL (190 pg/ml). In contrast, when a concentration of IL-4 (100 U/ml) able to increase intracellular cAMP was added at the beginning of the LGL culture in the presence of IL-2, an important decrease (88% inhibition) of TNF production was observed (22 pg/ml). Addition ofdBcAMP (10-4 M) at the initiation of the culture also consistently inhibited (92% inhibition) TNF production (15 pg/ml) by IL-2-stimulated LGL as compared to the control culture.
Discussion
The data presented in this report confirm earlier observations showing that IL-4 inhibits the capacity of human LGL to be activated by IL-2 and to differentiate into LAK effectors (5, (7) (8) (9) . Although some reports suggested that IL-4 acts at the induction phase of cytolytic activity (8, 9) , no conclusive explanation has been proposed to account for this inhibition. In the current study, we attempted to gain more detailed understanding of the mechanism by which IL-4 downregulates the capacity of IL-2 to generate LAK effectors.
Our findings clearly indicate that, when IL-4 is used in costimulation with IL-2, the marked suppression on LAK activity occurs concomitantly with a significant increase in intracellular cAMP levels in LGL. Our results support the hy- pothesis that cAMP could be involved in signal transduction of human IL-4 and provide additional insights on the inhibitory function of the cAMP pathway on the amplification and effector phase of the immune effector function (1 1-14) . It has recently been shown that IL-4 alone is able to trigger the differentiation of IL-2-prestimulated PBL into LAK effectors. In addition, our results indicate that IL-4 induces a nonsignificant increase of intracellular cAMP in IL- 2-prestimulated LGL, that already display LAK activity. These observations provide further support of the association of cAMP elevation with the inhibitory effect of IL-4 on LAK generation by resting
LGL and also point to the possible existence of distinct controls oftransduction pathways according to the activation state of the cells. It is well established that the elevation of intracellular cAMP generally causes the activation of a cAMP-dependent protein kinase A (13). This enzyme phosphorylates substrate proteins that may regulate the initiation process including activation of a receptor coupling signal transduction system and gene transcription. It has also been reported that elevation of cAMP levels antagonizes the IL-2-stimulated T cell progression ( 16) . It is conceivable therefore that the suppressive influence of cAMP through a cAMP-dependent protein kinase interferes with some intermediate biochemical events after IL-2 receptor triggering on LGL. For instance, cAMP may affect the protein kinase C activation and phosphorylation of some proteins associated with the development of functional expression by LAK effectors. It has been recently reported that down-modulation of protein kinase C correlates with a loss of LAK activity (26) . Furthermore, it has been shown that BSF-I interaction with its receptor activates a membrane associated protein kinase other than protein kinase C in resting B cells (27) . In this respect, the elucidation of the mechanisms by which IL-4 interferes with the adenylate cyclase system and the subsequent protein kinase stimulation could be of considerable importance.
Multiple putative roles have been advanced for serine esterases in cell mediated cytotoxicity (17, 18) . Our results indicate that IL-4 interferes with the IL-2-induced BLT-E activity in LGL. A similar inhibition of BLT-E activity also occured when LGL cultures were treated with dBcAMP further suggesting an involvement of this cyclic nucleotide in the IL-4-mediated inhibition of BLT-E activity. It should be stressed, however, that the inhibitory effect ofIL-4 on LAK activity was more pronounced than on BLT-E activity. This is consistent with a lack of association between the intensity of LGL cytotoxic function and the BLT-E enzymatic activity and in agreement with the concept that the killing pathway and the BLT-E induction may be under a distinct control. Our findings also indicate that IL-4 interferes with BLT-E activity in LGL but does not affect the basal cellular content of the enzyme in unstimulated LGL indicating that IL-4 mainly affects the IL-2-dependent part of the lytic potential of IL-2-activated LGL. These results are in contrast with a previous report in the murine model (8) indicating that stimulation of PBL with the combination ofIL-2 and IL-4 resulted in both marked increase of LAK cytotoxic capacity and BLT-E activity (8) .
Our studies also show another site of IL4 action on LAK generation by its capacity to inhibit TNF gene expression and TNF production by IL-2-stimulated LGL. This confirms previous observations suggesting that LAK development involves, at least in part, TNF production (22, 25) . It should be noted that dBcAMP and other cAMP inducing agents such as forskolin (not shown) also inhibited both TNF mRNA expression and TNF production by IL-2-activated LGL, confirming the involvement of cAMP in the IL-4-induced inhibition of LGL function. Although a recent report has demonstrated that human IL-4 impaired TNF-a gene expression by monocytes (28) , the inhibitory effect of IL-4 on the IL-2-induced TNF production under our experimental conditions is not due to contaminating monocytes in LGL preparation since Leu M3-positive cells represented < 0.5% of LGL preparation (not shown).
In conclusion, our data suggest that IL-4, presumably through the cAMP pathway, is able to affect gene transcription or posttranscriptional events involved in the acquisition ofthe LAK lytic competence by the LGL. Further studies will be required to clarify this issue. The understanding of IL-4 signaling pathway and of the cytokines induced cross-talk between cellular signaling pathways during LAK differentiation are ofconsiderable importance and may help to more precisely delineate the complex interplay of cytokines in cell-mediated cytotoxicity and their use in combination in antitumor therapy.
